FDA’s leadership void leaves biotech with renewed ‘uncertainty’
BioPharma Dive
Marty Makary's resignation leaves the agency with temporary directors in three top positions, and a number of newly instituted policies with an unclear future.
pharminent
May 13, 2026 (Last updated: May 16, 2026)
BioPharma Dive
Marty Makary’s resignation leaves the agency with temporary directors in three top positions, and a number of newly instituted policies with an unclear future.
